Preclinical experiments in humanized animal tumor models demonstrated antitumor activities of QL1706, with evidence of a functional dual blockade of both the PD-1 and CTLA-4 pathways (Additional file 1: Fig. S4). This evidence concerns the gene PDCD1 and neoplasm.